All Articles

The AOD-9604 dosage question is clearest when you stick to clinical evidence: once-daily oral regimens in real human trials, followed by a larger study that changed everything. Here's what actually moved the needle.

AOD-9604 keeps showing up because the idea is attractive: a narrower fat-loss peptide with less of the GLP-1 routine and a lower out-of-pocket barrier.